These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35119623)

  • 21. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
    Weber M; Binse I; Nagarajah J; Bockisch A; Herrmann K; Jentzen W
    Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):235-252. PubMed ID: 31298014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative performance evaluation of
    Wierts R; Jentzen W; Quick HH; Wisselink HJ; Pooters INA; Wildberger JE; Herrmann K; Kemerink GJ; Backes WH; Mottaghy FM
    Phys Med Biol; 2017 Dec; 63(1):015014. PubMed ID: 29116052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
    Huang SY; Bolch WE; Lee C; Van Brocklin HF; Pampaloni MH; Hawkins RA; Sznewajs A; DuBois SG; Matthay KK; Seo Y
    Mol Imaging Biol; 2015 Apr; 17(2):284-94. PubMed ID: 25145966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
    Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
    J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
    Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
    Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Tumor Control in
    Dewaraja YK; Devasia T; Kaza RK; Mikell JK; Owen D; Roberson PL; Schipper MJ
    J Nucl Med; 2020 Jan; 61(1):104-111. PubMed ID: 31147404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
    Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning.
    Pettinato C; Spezi E; Nanni C; Grassetto G; Monari F; Allegri V; Civollani S; Cima S; Zagni P; Mazzarotto R; Colletti PM; Rubello D; Fanti S
    Clin Nucl Med; 2014 Aug; 39(8):e367-74. PubMed ID: 24978332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosimetry in differentiated thyroid carcinoma (12-1402R).
    Minguez P; Genolla J; Celeiro JJ; Fombellida JC
    Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
    Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
    Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?
    Binse I; Poeppel TD; Ruhlmann M; Gomez B; Umutlu L; Bockisch A; Rosenbaum-Krumme SJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1011-7. PubMed ID: 26686334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosimetry during adjuvant
    Szumowski P; Abdelrazek S; Iwanicka D; Mojsak M; Sykała M; Żukowski Ł; Siewko K; Adamska A; Maliszewska K; Popławska-Kita A; Szelachowska M; Krętowski A; Myśliwiec J
    Sci Rep; 2021 Jul; 11(1):13930. PubMed ID: 34230618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
    Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM
    J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
    Chiesa C; Castellani MR; Vellani C; Orunesu E; Negri A; Azzeroni R; Botta F; Maccauro M; Aliberti G; Seregni E; Lassmann M; Bombardieri E
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):546-61. PubMed ID: 19910908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.
    de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma.
    Verburg FA
    Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):253-257. PubMed ID: 31271272
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of prompt gamma coincidence correction on absorbed dose estimation in differentiated thyroid cancer using 124I PET/CT imaging.
    Wierts R; Conti M; Claessen AGG; Herrmann K; Kemerink GJ; Binse I; Wildberger JE; Mottaghy FM; Backes WH; Jentzen W
    Nucl Med Commun; 2018 Dec; 39(12):1156-1164. PubMed ID: 30204643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.